Repligen
RGEN
#2045
Rank
โ‚ฌ7.97 B
Marketcap
141,70ย โ‚ฌ
Share price
-0.47%
Change (1 day)
5.44%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of September 2025 : โ‚ฌ0.59 Billion

According to Repligen 's latest financial reports the company's total debt is โ‚ฌ0.59 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ0.65 B2.42%
2023-12-31โ‚ฌ0.64 B63.3%
2022-12-31โ‚ฌ0.39 B21.99%
2021-12-31โ‚ฌ0.32 B44.35%
2020-12-31โ‚ฌ0.22 B-4.74%
2019-12-31โ‚ฌ0.23 B159.84%
2018-12-31โ‚ฌ90.46 M9.36%
2017-12-31โ‚ฌ82.71 M-8.67%
2016-12-31โ‚ฌ90.57 M
2005-03-31โ‚ฌ0.09 M34.1%
2004-03-31โ‚ฌ0.06 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novavax
NVAX
โ‚ฌ0.21 B-63.54%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ0.51 B-12.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ0.36 B-37.81%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ17.89 B 2,924.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ30.64 B 5,079.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ43.83 B 7,309.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ52.26 B 8,733.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.33 B-42.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ21.83 M-96.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ2.25 B 281.59%๐Ÿ‡บ๐Ÿ‡ธ USA